uniQure (NASDAQ:QURE) Reaches New 12-Month High After Analyst Upgrade

uniQure (NASDAQ:QUREGet Free Report)’s stock price reached a new 52-week high during mid-day trading on Tuesday after Raymond James upgraded the stock from an outperform rating to a strong-buy rating. Raymond James now has a $52.00 price target on the stock, up from their previous price target of $20.00. uniQure traded as high as $17.39 and last traded at $15.30, with a volume of 61370594 shares trading hands. The stock had previously closed at $7.30.

QURE has been the subject of several other reports. Cantor Fitzgerald increased their price objective on uniQure from $28.00 to $58.00 and gave the company an “overweight” rating in a research note on Tuesday. StockNews.com raised shares of uniQure to a “sell” rating in a report on Thursday, October 17th. HC Wainwright reaffirmed a “buy” rating and set a $25.00 price objective on shares of uniQure in a research note on Wednesday, November 6th. The Goldman Sachs Group cut their target price on uniQure from $10.00 to $9.00 and set a “neutral” rating on the stock in a research note on Wednesday, November 6th. Finally, Royal Bank of Canada reduced their price target on uniQure from $16.00 to $14.00 and set an “outperform” rating on the stock in a report on Wednesday, November 6th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating, three have given a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, uniQure currently has a consensus rating of “Moderate Buy” and an average price target of $27.33.

Read Our Latest Stock Report on uniQure

Institutional Investors Weigh In On uniQure

A number of large investors have recently added to or reduced their stakes in the stock. Vanguard Personalized Indexing Management LLC increased its holdings in uniQure by 21.0% in the 2nd quarter. Vanguard Personalized Indexing Management LLC now owns 13,301 shares of the biotechnology company’s stock worth $59,000 after acquiring an additional 2,306 shares in the last quarter. China Universal Asset Management Co. Ltd. boosted its position in shares of uniQure by 57.0% in the third quarter. China Universal Asset Management Co. Ltd. now owns 10,093 shares of the biotechnology company’s stock worth $50,000 after purchasing an additional 3,663 shares during the period. Geode Capital Management LLC increased its stake in shares of uniQure by 1.3% in the third quarter. Geode Capital Management LLC now owns 508,602 shares of the biotechnology company’s stock worth $2,509,000 after purchasing an additional 6,362 shares in the last quarter. American Century Companies Inc. raised its position in shares of uniQure by 14.6% during the 2nd quarter. American Century Companies Inc. now owns 67,699 shares of the biotechnology company’s stock valued at $303,000 after purchasing an additional 8,642 shares during the period. Finally, RTW Investments LP purchased a new position in shares of uniQure during the 3rd quarter valued at $49,000. Institutional investors own 78.83% of the company’s stock.

uniQure Price Performance

The stock has a market cap of $745.72 million, a PE ratio of -1.47 and a beta of 0.89. The firm’s fifty day moving average price is $6.20 and its 200 day moving average price is $6.08. The company has a quick ratio of 6.51, a current ratio of 6.51 and a debt-to-equity ratio of 0.92.

uniQure (NASDAQ:QUREGet Free Report) last posted its earnings results on Tuesday, November 5th. The biotechnology company reported ($0.91) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.12) by $0.21. The firm had revenue of $2.29 million for the quarter, compared to the consensus estimate of $2.73 million. uniQure had a negative net margin of 837.80% and a negative return on equity of 188.82%. As a group, equities analysts expect that uniQure will post -3.74 EPS for the current fiscal year.

uniQure Company Profile

(Get Free Report)

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.

Read More

Receive News & Ratings for uniQure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for uniQure and related companies with MarketBeat.com's FREE daily email newsletter.